Predicting Treatment Response to Exposure Therapy Using Carbon Dioxide

Status Completed

Clinical Trial Summary

Anxiety disorders affect over a quarter of the population, yet very little is known about the variables that predict treatment outcome. The planned study explores whether a patient's response to a physiological test involving inhalation of carbon dioxide predicts their response to exposure therapy.

Clinical Trial Description

Anxiety Sensitivity (AS) refers to an individual's fear of experiencing anxiety-related symptoms (e.g., dyspnea or heart palpitations) and is a core construct underlying the initiation and maintenance of pathological anxiety. Recent evidence suggests that reducing AS may be critical for the prevention and treatment of anxiety across diagnostic categories. Exposure therapy, an important component of cognitive behavioral therapy (CBT), is one of the most effective treatments for reducing AS, and has been shown to improve symptoms across a number of different anxiety disorders. Meta-analyses reveal an approximately 50% treatment response rate, with the remaining half of patients showing either no response or dropping out of treatment early. Unfortunately, there is a paucity of research exploring which variables predict treatment outcome and there are currently no tests for predicting which patients would benefit the most from exposure therapy. In this study, participants will complete two sessions of a carbon dioxide (CO2) habituation paradigm, a safe and noninvasive physiological test that entails repeated exposures to single vital capacity inhalations of 20% CO2. Both CO2 testing sessions will be completed within a 72-hour time period. Patients then complete a 10-week group-based exposure therapy to determine whether an individual's degree of habituation to CO2 predicts treatment outcome. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03925987
Study type	Interventional
Source	Laureate Institute for Brain Research, Inc.
Contact
Status	Completed
Phase	N/A
Start date	June 7, 2018
Completion date	July 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03420456` - Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study	N/A
Active, not recruiting	`NCT05530642` - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel	N/A
Withdrawn	`NCT02382224` - Worry Exposure for Generalized Anxiety Disorder	N/A
Completed	`NCT02256566` - Cognitive Training for Mood and Anxiety Disorders	N/A
Completed	`NCT02306356` - Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting	N/A
Completed	`NCT01958788` - Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder	N/A
Completed	`NCT01681329` - Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder	N/A
Completed	`NCT01337713` - Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)	N/A
Completed	`NCT01201967` - A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients	Phase 4
Completed	`NCT01342120` - PHARMO Institute Seroquel Safety Study	N/A
Completed	`NCT01971203` - Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat	N/A
Completed	`NCT00961298` - An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder	Phase 4
Completed	`NCT01203293` - Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector	Phase 1
Completed	`NCT00744627` - Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.	Phase 3
Completed	`NCT00711737` - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months	N/A
Terminated	`NCT01244711` - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines	Phase 4
Completed	`NCT00515242` - Therapeutic Massage for Generalized Anxiety Disorder	Phase 1/Phase 2
Completed	`NCT00525226` - Evaluating the Effects of Stress in Pregnancy	N/A
Completed	`NCT00537615` - An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers	Phase 1
Completed	`NCT00368745` - Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.	Phase 3